regardless of positive clinical results, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing considerable opposition from pharmacy benefit managers. These https://qasimhtnc893685.webbuzzfeed.com/42376685/the-vyndamax-faces-is-encountering-pbm-challenges-a-look-at-reimbursement-battles